Vectory Therapeutics received FDA IND clearance for VTX‑002, a vectorized antibody designed to target TDP‑43 pathology in amyotrophic lateral sclerosis (ALS), clearing the way for a Phase I/II PIONEER‑ALS study. Vectory described VTX‑002 as a first‑in‑class approach aiming to modulate intracellular proteinopathy via vectorized delivery. The company plans dose-escalation to evaluate safety, tolerability and pharmacodynamic markers in ALS patients, with early biomarker readouts expected to guide dose selection for expansion cohorts. Vectory framed the IND as a validation of its vectorized antibody platform and a step toward novel approaches for neurodegenerative proteinopathies.